A Randomized Placebo-Controlled Trial of Combination Therapy With Post-triple-antibiotic-therapy Fecal Microbiota Transplantation and Alginate for Ulcerative Colitis: Protocol

Ishikawa, Dai; Zhang, Xiaochen; Nomura, Kei; Seki, Natsumi; Haraikawa, Mayuko; Haga, Keiichi; Shibuya, Tomoyoshi; Nagahara, Akihito

doi:10.3389/fmed.2022.779205

Cited by 5 publications

(8 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…determined that the dietary fiber apple pectin administered to UC patients after FMT can maintain diversity of the intestinal microbiota. [ 59,67 ] This study prompted Ishikawa et al. to use alginate to further improve the efficacy of A‐FMT and remission rate, and to delay the microbiota loss in UC patients.…”

Section: Gut Microbiotamentioning

confidence: 99%

“…to use alginate to further improve the efficacy of A‐FMT and remission rate, and to delay the microbiota loss in UC patients. [ 59 ] Alginate is algenic acid, a soluble dietary fiber, polysaccharide present in brown algae, [ 68 ] was previously shown to enhance the growth of intestinal bacteria and upon fermented by gut bacteria to produce SCFAs, thus is beneficial to the intestines. [ 59,69 ] In this clinical study by Ishikawa et al.…”

Section: Gut Microbiotamentioning

confidence: 99%

“…With minimal invasiveness, FMT involves the transfer or transplanting of intestinal microbiota from healthy donors to patients with dysbiosis in an attempt to restore normal intestinal functions of microbiota. [59] Previous clinical randomized studies evaluated the effectiveness of FMT, with promising results in patients achieving remission and maintaining remission at 12 months. [60,61] In the study by Ishikawa et al, the authors used a triple antibiotic therapy regiment for two weeks after one of FMT via colonoscopy.…”

Section: Gut Microbiotamentioning

confidence: 99%

“…[60,61] In the study by Ishikawa et al, the authors used a triple antibiotic therapy regiment for two weeks after one of FMT via colonoscopy. [59] This study utilized pretreatment of the triple antibiotic therapy and post-treatment of alginate in addition to FMT. The triple antibiotic therapy, a combination of amoxicillin, fosomycin, and metronidaxole (AFM), or a combination of amoxicillin, tetracycline, and metronidaxole (ATM) was previously shown to induce remission in UC patients with AFM offering less side effects than ATM due to tetracycline.…”

Section: Gut Microbiotamentioning

confidence: 99%

“…[63][64][65][66] A study by Wei et al determined that the dietary fiber apple pectin administered to UC patients after FMT can maintain diversity of the intestinal microbiota. [59,67] This study prompted Ishikawa et al to use alginate to further improve the efficacy of A-FMT and remission rate, and to delay the microbiota loss in UC patients. [59] Alginate is algenic acid, a soluble dietary fiber, polysaccharide present in brown algae, [68] was previously shown to enhance the growth of intestinal bacteria and upon fermented by gut bacteria to produce SCFAs, thus is beneficial to the intestines.…”

Section: Gut Microbiotamentioning

confidence: 99%

See 4 more Smart Citations

Evolving Experimental Platforms to Evaluate Ulcerative Colitis

et al. 2022

View full text Add to dashboard Cite

tissue thus altering tissue integrity, anatomy, and physiology subsequently affecting the overall health-related quality of life (HRQoL) of afflicted individuals. [1][2][3] It is estimated that the lifetime financial loss associated with the typical UC patient can be greater than $1 million/patient to cover direct and indirect medical expenses including treatment, hospitalizations, and general medical care. [3][4][5][6][7] As an example, vedolizumab and adalimumab treatment for UC had total direct medical costs of $100 022 and $151 133, respectively, per patient. [8] This number varies greatly depending upon the severity of the disease with a greater expense attributed to those exhibiting a poor clinical disposition. At the domestic level, the total cost to treat UC is estimated to be between $4-14 billion per year which seems to rise on an annual basis. [3,6,7] The specific etiological basis regarding the initiation and progression of UC is currently unknown. Physical manifestations of severe UC take the form of ulcerations affecting the mucosal lining, specifically along the length of the affected large intestine and rectum as depicted in Figure 1. These lesions contain an overabundant accumulation of innate and adaptive immune cells, including T cells, that promote an inflammatory environment Ulcerative colitis (UC) is a multifactorial disease defined by chronic intestinal inflammation with idiopathic origins. It has a predilection to affect the mucosal lining of the large intestines and rectum. Management of UC depends upon numerous factors that include disease pathogenesis and severity that are maintained via medical or surgical means. Chronic inflammation that is left untreated or managed poorly from a clinical stance can result in intestinal ulceration accompanied by resulting physiological dysfunction. End-stage UC is mediated by surgical intervention with the resection of diseased tissue. This can lead to numerous health-related quality of life issues but is considered a curative approach. Regimens to treat UC are ever evolving and find their basis within various platforms to evaluate and treat UC. Numerous modeling systems have been examined to delineate potential mechanisms of action. However, UC is a heterogenous disease spanning unknown genetic origins coupled with environmental factors that can influence disease outcomes and related treatment procedures. Unfortunately, there is no one-size-fits-all model to fully assess all facets of UC. Within the context of this review article, the utility of various approaches that have been employed to gain insight into different aspects of UC will be investigated.

show abstract

Section: Gut Microbiotamentioning

confidence: 99%